[00:00]
Adam:
[00:03]
it's Adam Ragusea, and yes, my weight is yo-yoing
[00:12]
grew a social movement to de stigmatize fatness.
[00:19]
Advance Fat Acceptance, which most famously
[00:26]
bigger seats for big bodied people. You also get
[00:32]
which pushes this public health frame
[00:39]
health at every size people observed is that
[00:45]
discriminated against in the healthcare system.
[00:52]
and it goes something like this. What did the
[00:56]
wound? Have you tried diet and exercise? It's
[01:04]
this claim that doctors tend to look at a person
[01:09]
their obesity. And what obese people have
[01:16]
health problems that have nothing to do with my
[01:20]
Number two, even if my health problems are related
[01:29]
by the study outcomes, it is nearly impossible
[01:35]
off without serious medical help, so let's not
[01:41]
almost impossible before you start treating me
[01:49]
Over on the other side of this particular
[01:55]
saying this is all hogwash, it's very well
[01:59]
a lot of extra body fat have much worse health
[02:06]
It is not possible to be healthy at every size.
[02:14]
seen an enlightened consensus emerge where we
[02:21]
of bad things, but fatness is not necessarily the
[02:29]
diabetes, and kidney disease, and non-alcoholic
[02:35]
in a dense web of causality that we now call
[02:42]
is at most an imperfect proxy for the total
[02:48]
to be fat, but they're not always fat, and the
[02:54]
is murky. Anyway, I think the emergence of that
[03:01]
bit between the fat acceptance crowd and the fat
[03:10]
Speaking of consensus, we cannot seem to form one
[03:18]
GLP-1 drugs, but that's not quite right. These
[03:26]
that all our bodies produce to make us feel full
[03:32]
drugs also imitate different peptides like GIP,
[03:38]
and there are more things like that on
[03:42]
incomplete. It's like calling all of my cups
[03:50]
You could call these drugs incretin mimetics.
[03:56]
regulate blood sugar and appetite are known
[04:02]
imitates another thing, which is what these
[04:08]
But, incretin mimetic is even harder to say out
[04:17]
hasn't caught on among the general public.
[04:24]
weight loss drugs because they are the only safe
[04:32]
and long-lasting effects. These are the only
[04:39]
to any reasonable, real world standard of what it
[04:47]
them the weight loss drugs, they're the weight
[04:52]
views these drugs with some amount of suspicion.
[04:59]
of money selling false hope to generations of
[05:07]
which seems to be the case this time, the body
[05:12]
will reinforce a toxic, thin ideal in society.
[05:21]
to that ideal since, hey man, all you need to
[05:27]
which is still extremely expensive and
[05:34]
I am, as you can tell, very sympathetic to the
[05:41]
the ongoing research on these drugs points to
[05:47]
should view as something of a vindication. The
[05:55]
because these drugs work even if you aren't
[06:03]
of fatness. In clinical trials, in people who
[06:09]
to lose weight, we are still seeing dramatic
[06:15]
health, brain health, addiction, substance abuse
[06:22]
whys and the hows, but it sure seems like these
[06:29]
weight to be essentially correct. If a drug treats
[06:36]
impacting weight, if you get healthier on these
[06:42]
the same, that would indicate that weight is only
[06:52]
I think that body acceptance advocates should
[06:57]
just about fatness. It might not even be primarily
[07:05]
denominator here is the hormones that influence
[07:12]
psychologically. We are evolved to live a
[07:19]
the time. And so to be healthy, our bodies seem
[07:28]
or when we are not getting the hormonal signal
[07:37]
these very complicated biological systems
[07:43]
drugs as a miracle cure, and we certainly
[07:51]
I am curious about the side effects that we're
[07:57]
are taking these drugs. I'm curious about how
[08:03]
after decades of use. And I am curious about why
[08:13]
A great expert on the internet to follow for
[08:21]
practitioner. That is a nurse whose level of
[08:26]
in the US system. He doesn't need to go through
[08:31]
David says on my channel should be construed as
[08:38]
smart guy who deals with these drugs every day in
[08:44]
reading and posting about the latest research.
[08:51]
his social links are in the description.
[08:55]
be some ongoing conversations with Nurse David
[09:02]
what kind of side effects are we seeing?
[09:05]
I mean, the biggest one, and the trial data
[09:11]
just informally call it the big four. So whenever
[09:17]
they'll almost always have nausea,
[09:21]
Adam:
[09:22]
medication that I've heard can treat all four
[09:26]
David:
[09:30]
add is usually some form of heartburn. You'll
[09:35]
my patients. You can look on Reddit, or really any
[09:42]
burps, which is just the drugs delay your gastric
[09:50]
forward, and so you get a little fermentation.
[09:54]
Yeah.
[09:57]
But even that, same thing, there are ways of
[10:04]
cooking side of things, pineapple, papaya.
[10:07]
The enzymes.
[10:08]
Yeah, the enzymes will help. And people look
[10:13]
it'll work." But yeah, that's one thing with
[10:20]
manageable.
[10:21]
Yeah.
[10:22]
A lot of it too in the trials is their goal
[10:26]
let's lose the most amount of weight as fast as we
[10:35]
they're really actually quite tolerable.
[10:41]
the actual absolute rate of side effects, even
[10:49]
rate. And over time, because most of the drug
[10:57]
you'll watch it just slowly drops away as
[11:04]
Adam:
[11:06]
Like the new normal where we are all expected
[11:12]
real jobs. Love that, but you can make it more
[11:18]
easiest way to build a website. Do you still
[11:25]
I'm talking to in this video? I know who he is
[11:34]
I noticed it, and now he's on my channel with
[11:39]
things work. If you want to be discovered,
[11:45]
a website from Squarespace does just that.
[11:51]
to help the AI chatbots find your site and
[11:57]
building the site yourself is just stupid easy at
[12:02]
prompt and just start tweaking it until it's
[12:08]
email marketing, everything that you can need
[12:12]
around with a site for free. When you're ready
[12:18]
name, save yourself 10% with my code RAGUSEA.
[12:24]
Squarespace. Anyway, we were talking
[12:28]
associated with the new weight loss drugs.
[12:33]
muscle wasting, which I've understood to
[12:38]
muscle loss that you would expect with
[12:42]
David:
[12:44]
medicine research, they will reference something
[12:52]
they mean you should... If you were to just crash
[13:01]
mass and about 25% lean mass.
[13:04]
Yeah.
[13:04]
And when you look at these drugs, it's
[13:11]
lean mass loss and the rest is fat mass loss.
[13:18]
definition of lean mass. It depends on, are you
[13:26]
the conversation with patients like, "If you are
[13:32]
in and at least do resistance training." Those are
[13:39]
things that will at least preserve your functional
[13:44]
Adam:
[13:47]
by bodybuilders and people like that.
[13:51]
Yes.
[13:52]
They know that when you diet down, you're going
[13:57]
the weights and if you keep getting protein,
[14:01]
David:
[14:03]
Adam:
[14:05]
that are concerning you so far?
[14:08]
There's a slightly increased risk of gallstones
[14:18]
also more related to the weight loss and not
[14:24]
but you lose weight rapidly and sometimes your
[14:31]
patients can get their gallbladder out and then
[14:37]
happened.
[14:39]
And then there's the big unknown that not
[14:44]
which is what happens to people when
[14:47]
David:
[14:53]
there is probably a reasonable subset of diabetics
[15:00]
time just.
[15:01]
At this point.
[15:02]
Yeah. I mean, liraglutide or Victoza, that was FDA
[15:10]
Adam:
[15:13]
David:
[15:15]
generic now. That's how long it's been around. So
[15:22]
in 2017, so we're going on 10 years for that even.
[15:31]
for a while. But even the clinical trials, the
[15:37]
and obviously we just continue to see a benefit as
[15:44]
any evidence to back this up.
[15:47]
Very scientific.
[15:48]
But also, I mean, it doesn't make... Just
[15:54]
Adam:
[15:55]
argument. There you go. Go ahead.
[15:57]
Yeah. On a mechanistic argument, there shouldn't
[16:04]
drug class, with statins, we know the longer
[16:11]
cardiovascular diseases.
[16:12]
Sure yeah.
[16:13]
And so I have a feeling it's going to be the same
[16:19]
20% of your body weight and you stay on it for
[16:25]
probably have less comorbid conditions. You'll
[16:33]
and actually there's already starting
[16:39]
Adam:
[16:41]
David:
[16:47]
Adam:
[16:50]
quality adjusted life year. We don't just want to
[16:57]
and QALY is a crude way of measuring that. It's
[17:03]
you. That's a QALY. Anyway.
[17:05]
The QALY data is already starting to line up that
[17:11]
they do start paying for themselves, even with the
[17:21]
and actuaries everywhere, that's
[17:24]
Adam:
[17:26]
to make a mechanistic argument, and also I suppose
[17:32]
a receptor in your body and you pummel it.
[17:35]
Yeah.
[17:36]
With stimulus a little bit more than it would
[17:42]
weird things happening among them. It's just going
[17:49]
that receptor feel anything.
[17:51]
Yeah.
[17:52]
Are we not seeing that with these drugs? We're not
[17:56]
system just equilibrates to it?
[17:59]
There was a cardiovascular outcomes trial called
[18:07]
last year, and it was almost five year long
[18:13]
at cardiovascular outcomes. And they included
[18:21]
Adam:
[18:21]
David:
[18:24]
was about four and a half year period and there's
[18:30]
down, and if you look at the error bars and the
[18:39]
15,000 patient trial and no one is... I don't want
[18:49]
regaining weight, not requiring a higher dose,
[18:58]
above my pay grade in terms of understanding, but
[19:04]
for some reason, there's just not that
[19:09]
with cannabinoids or opioids or various other.
[19:21]
GLP-1 as a receptor is so integral to just
[19:31]
Adam:
[19:31]
David:
[19:34]
it took pharmacology to realize, oh, hey, this
[19:45]
Simplistic understanding is, sure, it suppresses
[19:50]
but I mean, it is-
[19:51]
Tip of the iceberg.
[19:52]
Yeah, half inch view. I mean, I'm working on
[20:01]
infects, and I've been writing for a month and
[20:05]
it down to regular, in English, but also it's
[20:11]
I'm like, "Oh, wait, there's another
[20:17]
I actually found an evolutionary development paper
[20:27]
development of the GLP-1 class, or I guess I shape
[20:38]
So you get GLP-1, which everyone knows about. You
[20:47]
and you also get glucagon, and then you get a
[20:52]
that family of those three hormones are so deeply
[21:04]
really great paper that talks about some of the
[21:11]
loss, and it had the actual amino acid sequences
[21:20]
off from the primate family tree, and you could
[21:30]
Even some of the bony fish glucagon is still
[21:36]
human and get an effect. So clearly evolution was
[21:44]
I think that's my speculation as to why you don't
[21:50]
actually mission-critical to keeping you alive.
[21:55]
Well, I suppose all of that is a lot of reason
[21:59]
caution.
[22:00]
Yes.
[22:00]
If we're dealing with such a
[22:03]
David:
[22:04]
Adam:
[22:11]
obesity as we know it would be over as a pandemic
[22:21]
I've got seven more years for that admittedly
[22:31]
on schedule you reckon we are. I actually
[22:37]
it is preceding the way I imagined, where you're
[22:45]
David:
[22:52]
Adam:
[22:54]
David:
[22:56]
hullabaloo about how the rate of obesity in the
[23:04]
it's like, is that the drugs? Is that the first
[23:11]
we're starting to see a downward deflection in the
[23:20]
but at the same time, I mean, some of the
[23:26]
which is a triple agonist that will have phase
[23:34]
I mean, it's mid-April when we're recording this,
[23:39]
of June, so not too long for that. And that drug
[23:47]
Adam:
[23:49]
bariatric surgery, you mean?
[23:50]
Yeah.
[23:51]
And by triple agonist, you mean it's
[23:55]
David:
[23:57]
it acts on GIP, and then it acts on glucagon so
[24:07]
two data showed 24% weight loss at 48 weeks. There
[24:14]
weight loss at 68 weeks with patients still losing
[24:21]
data published in June will have an 80-week and
[24:30]
I mean, 29%, you're one point away from 30%,
[24:38]
loss. 30% to 35% is usually what most bariatric
[24:47]
have a drug that has that level of efficacy.
[24:56]
it's pretty reasonable to expect obesity
[25:03]
there are so many other drugs in development that
[25:11]
loss, which again, like that's going to drive a
[25:18]
and not obese anymore. So yeah, I mean, by 2035,
[25:27]
obesity.
[25:28]
What are you most excited about looking ahead?
[25:32]
I mean, so the drug that I just mentioned,
[25:42]
the mechanism alone, I mentioned it, it acts on
[25:51]
field, they're like, "Oh, that's the drug we
[25:59]
that in this case, when you are depressing the
[26:06]
the opposite happens so it increases insulin
[26:15]
as counterintuitive as that sounds, but it also
[26:24]
like a starvation signal to your body and you
[26:31]
trials were as ethical as they are now where
[26:38]
but glucagon is the signal that comes through when
[26:43]
their insulin levels drop, and it forces
[26:50]
Adam:
[26:51]
David:
[26:54]
so GLP-1 basically reduces your intake through
[27:02]
basically telling your body, "Hey, grab the
[27:08]
Adam:
[27:12]
decline in available calories. This is winter,
[27:17]
our whole system to this new reality."
[27:19]
Yeah. So you get less intake and then you are
[27:26]
for weight loss. And then side benefit, because
[27:34]
so you will see pretty profound, again, going
[27:42]
they saw almost 25% drop in LDL cholesterol, the
[27:48]
taking a statin medication. So I look at it as,
[27:54]
lose weight and it drops your cholesterol like
[28:00]
Adam:
[28:00]
David:
[28:04]
a clinician like, "Oh, hey, you can take this one
[28:12]
Adam:
[28:15]
you've met Nurse David and he's going to be our
[28:21]
Check his blog and his socials in the description.
[28:26]
to treat major depressive disorder, bipolar,
[28:32]
Like the man said, these drugs work on your
[28:39]
good choices with your brain and your body,